Publication year
2022Source
Annals of Internal Medicine C.2, 175, 5, (2022), pp. 744-746ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Clinical Pharmacy
Journal title
Annals of Internal Medicine C.2
Volume
vol. 175
Issue
iss. 5
Page start
p. 744
Page end
p. 746
Subject
Radboudumc 4: lnfectious Diseases and Global Health RIHS: Radboud Institute for Health Sciences; Clinical Pharmacy - Radboud University Medical CenterAbstract
Nirmatrelvir–ritonavir (NMV/r) is now being used to treat high-risk patients with mild to moderate COVID-19. This article provides advice to clinicians regarding recognition of medications likely to interact with NMV/r and suggests approaches to managing such drug–drug interactions. An algorithm is provided to assist in decision making.
This item appears in the following Collection(s)
- Academic publications [242839]
- Faculty of Medical Sciences [92293]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.